TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9141518
Drug: MK-386 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 50 mg
Study: 8153915
Drug: Aminophylline (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (administered continuously for 48 hours after surgery)
Study: 8153915
Drug: Aminophylline (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (administered for 24 hours after cholecystectomy)
Study: 8153915
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group, administered for 24 hours after cholecystectomy)
Study: 25614600
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (2 μg·min(‐1)·kg(‐1)) at rest
Study: 25614600
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion during handgrip (HG) exercise
Study: 23940227
Drug: FLAG-Ida (fludarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAG-Ida (fludarabine, cytarabine, G-CSF, idarubicin)
Study: 23940227
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (1.5 g/m2 or 3 g/m2)
Study: 23940227
Drug: Cytarabine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (1.5 g/m2)
Study: 18340256
Drug: Minimal-contact, delayed-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-contact, delayed-treatment control condition
Study: 12665158
Drug: Dihydrocodeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine (60 mg single dose)
Study: 9151543
Drug: Various concurrent
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various concurrent recruitment methods
Study: 9151543
Drug: Complex trial
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex trial designs (e.g., pre-randomization placebo run-in, split-mouth designs)
Study: 8400972
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone + 1 mg gemeprost
Study: 8400972
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mifepristone + 1 mg gemeprost
Study: 8400972
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone + 1 mg gemeprost
Study: 31654548
Drug: Human fibrinogen
Normalized name: Human fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human fibrinogen concentrate (HFC; 4 g)
Study: 31654548
Drug: Cryoprecipitate (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprecipitate (two pools of 5 units, approximately 4.0-4.6 g fibrinogen)
Study: 26354542
Drug: Improving dietary
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improving dietary quality (increased fruit by +1 serving; 150 g/d, vegetables by +2 servings; 150 g/d, and dairy by +1 serving; 200-250 g/d)
Study: 20354496
Drug: Low-volume zero-balanced
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume zero-balanced ultrafiltration (35 mL/kg)
Study: 18207289
Drug: LGT/DEN4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGT/DEN4 vaccine (10^3 PFU)
Study: 16607233
Drug: Epoetin alfa,
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa, 40,000 IU, administered subcutaneously once weekly (n=48)
Study: 12869080
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral baclofen
Study: 8605131
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg subcutaneously)
Study: 8605131
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg subcutaneously) for 8 weeks
Study: 8605131
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (Goserelin and Danazol)
Study: 6355421
Drug: Captopril (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.5, 1.0, and 2.0 mg/kg)
Study: 6355421
Drug: Captopril (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (after 1 week of treatment)
Study: 3987782
Drug: Prazosin once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin once daily
Study: 3987782
Drug: Prazosin twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin twice daily
Study: 30081390
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus twice-weekly medication reminders by SMS (n=62)
Study: 30081390
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n=70)
Study: 26565928
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) program, 7-week duration
Study: 26401779
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (100 mg/day)
Study: 23818206
Drug: Montelukast tablets
Normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast tablets and theophylline
Study: 12828502
Drug: SLI‐381 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI‐381 10, 20 or 30mg once daily
Study: 10866908
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion at 10 mL/h (Group 1)
Study: 10866908
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion at 5 mL/h plus PCA boluses (2.5 mL/30 min) (Group 2)
Study: 10866908
Drug: PCA boluses
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA boluses only (10 mL/60 min) (Group 3)
Study: 9103270
Drug: Brussels sprouts
Normalized name: Brussels sprouts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brussels sprouts (300 g per day)
Study: 9103270
Drug: Glucosinolate-free vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosinolate-free vegetables (300 g per day)
Study: 3095082
Drug: Ritanserin 20
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 20 mg
Study: 3095082
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg and 20 mg)
Study: 31515632
Drug: NZBC extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NZBC extract (600 mg day-1 CurraNZ™ containing 210 mg anthocyanins)
Study: 16647134
Drug: Pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib sodium (1 mg)
Study: 16647134
Drug: Pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib sodium (3 mg)
Study: 12960445
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg hydroxy‐progesterone caproate and 10 mg oestradiol valerate on days 2, 6, 10 and 14 after embryo transfer (group 2, n = 411)
Study: 16941701
Drug: PEG-interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-interferon alpha-2b (PEG-IFN) monotherapy
Study: 10743815
Drug: Bilateral SI
Normalized name: SIS-101-ADO
DrugBank: SIS-101-ADO (DB18085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral SI joint injections of triamcinolone hexacetonide (40 mg/joint) under computer tomographic guidance
Study: 10743815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly mentioned, but implied as patients without treatment)
Study: 8614505
Drug: d-cycloserine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine (15 mg)
Study: 1390591
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (40 mg/day) + n-3 polyunsaturated fatty acids (5.3 g eicosapentaenoic and docosahexaenoic acids)
Study: 1390591
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (5.3 g)
Study: 17595895
Drug: Ciprofloxacin test
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin test formulation (Novell Pharmaceutical Laboratories, Indonesia)
Study: 17595895
Drug: Ciprofloxacin reference
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin reference formulation (Quimica Farmaceutica Bayer, Spain)
Study: 12495602
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 to 2 g IV twice daily or three times a day for 3 to 21 days
Study: 12495602
Drug: Broad-spectrum combination
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum combination therapy (IV ampicillin, cephalothin, or ceftriaxone +/- aminoglycoside) for 3 to 21 days
Study: 12495602
Drug: Broad-spectrum combination
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum combination therapy
Study: 9577999
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose gabapentin monotherapy (3,000‐4,800 mg/day)
Study: 9327485
Drug: Monthly newsletter
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly newsletter
Study: 2021990
Drug: Diphenhydramine 40
Normalized name: diphenhydramine Oral Capsule [40 Winks]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 40 mg iv pretreatment with cimetidine 200 mg iv
Study: 2021990
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg iv without diphenhydramine pretreatment
Study: 7214686
Drug: Oxatomide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (30 mg/capsule, 2-4 capsules daily)
Study: 7214686
Drug: Chlorpheniramine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (5 mg/capsule, 2-4 capsules daily)
Study: 30741797
Drug: Relugolix (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (40 mg, oral, once daily)
Study: 30741797
Drug: Leuprorelin (1.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin (1.88 mg or 3.75 mg, monthly injection)
Study: 27749616
Drug: Landmark-guided steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landmark-guided steroid injection (40 mg of methylprednisolone)
Study: 23653426
Drug: 5-mg donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg donepezil
Study: 23653426
Drug: 7.5-mg donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-mg donepezil
Study: 21854068
Drug: Pea protein
Normalized name: Pea Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea protein hydrolysate (PPH) administered orally at doses of 100 and 200 mg/kg body weight to SHR; 3-week randomized double-blind placebo-controlled trial in humans.
Study: 21854068
Drug: Unhydrolyzed pea
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unhydrolyzed pea protein isolate (PPI) administered orally to SHR.
Study: 15792017
Drug: VIBOVITmama supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIBOVITmama supplementation (15 mg of zinc, 2 mg of copper, 20 microg of selenium)
Study: 3013265
Drug: Enalapril 20-40
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20-40 mg plus hydrochlorothiazide 25-100 mg
Study: 3013265
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg plus hydrochlorothiazide 25-100 mg
Study: 6355186
Drug: Prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (15 mg/d per subject for 7 days)
Study: 24313916
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 100 mg plus MTX
Study: 24313916
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg plus MTX
Study: 24313916
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg plus MTX
Study: 17584318
Drug: Cyclosporin administered
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin administered before meals (group B)
Study: 17584318
Drug: Cyclosporin administered
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin administered after meals (group A)
Study: 11238232
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ETEC vaccine
Study: 11238232
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of ETEC vaccine
Study: 11238232
Drug: Two full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two full vaccine doses
Study: 11238232
Drug: One-third of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-third of a full dose of CFA-ETEC bacteria
Study: 9840528
Drug: Liver embolization
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver embolization with gel foam powder
Study: 30536797
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension formulations
Study: 30536797
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product of posaconazole oral suspension
Study: 26001337
Drug: Relamorelin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin (100 μg/d, given subcutaneously)
Study: 18773845
Drug: Aminobisphosphonates as
Normalized name: (dichloromethylene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminobisphosphonates as preventive treatment at the time of diagnosis of bone metastatic prostate cancer
Study: 18773845
Drug: Local treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatments (external beam radiotherapy, bone surgery) and systemic treatments (androgen deprivation, chemotherapy)
Study: 12709725
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg subcutaneous etanercept twice weekly for 24 weeks
Study: 12709725
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg subcutaneous etanercept twice weekly for 24 weeks
Study: 10932442
Drug: Integrated mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated mental health and substance use treatment program
Study: 8981131
Drug: dl-norgestrel (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-norgestrel (2 mg) with ethinyl oestradiol (200 micrograms)
Study: 8981131
Drug: levonorgestrel (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: levonorgestrel (1 mg) with ethinyl oestradiol (200 micrograms)
Study: 3908726
Drug: S6472 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 (750 mg b.i.d.)
Study: 3908726
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) (750 mg t.i.d.)
Study: 27455316
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry concentrate (MC) supplementation (30 mL twice per day for 8 days)
Study: 21832285
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (irinotecan with either bolus or infused 5-fluorouracil)
Study: 19200959
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG
Study: 17587713
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of acetylcholine
Study: 17587713
Drug: hs-CRP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP > or = 2 mg/L
Study: 2533802
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) plus diazepam (5 mg)
Study: 2533802
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) plus meclophenoxate (100 mg)
Study: 2533802
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 g/kg) plus placebo
Study: 31054159
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (400 iU daily) drops
Study: 31424481
Drug: Clopidogrel-Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-Aspirin
Study: 25948166
Drug: OSTAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSTAP block with 20 ml 0.25% bupivacaine
Study: 25948166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (paracetamol, tenoxicam, and tramadol as required)
Study: 20519697
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg day(-1) orally for 4 weeks)
Study: 20519697
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg day(-1) orally for 4 weeks)
Study: 11590500
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (1.2 million IU/m2 once daily) in conjunction with HAART
Study: 9547441
Drug: Nebivolol 2.5
Normalized name: nebivolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 2.5 mg
Study: 8147960
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin treatment
Study: 2897299
Drug: Bisoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (100 mg)
Study: 26707134
Drug: 0.25 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 μg/day calcitriol (n=48)
Study: 22261439
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of B vitamin supplementation and exercise training for 6 weeks
Study: 20437565
Drug: Memantine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (40 mg/day)
Study: 10630348
Drug: Neural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural therapy (injection of local anesthetic without adrenaline into specific trigger points)
Study: 8520623
Drug: Norethindrone (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone (low-dose therapy)
Study: 2239806
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 100 mg/m2 daily by constant infusion for 5 days
Study: 2239806
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 150 mg/m2 daily by constant infusion for 5 days
Study: 2239806
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 daily for 3 days plus etoposide 200 mg/m2 daily by constant infusion for 5 days
Study: 2239806
Drug: Mitoxantrone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone plus etoposide (various doses)
Study: 28303900
Drug: Amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (20 mg)
Study: 26235968
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/day) for 6 months
Study: 26235968
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (25 mg daily) for 6 months
Study: 26235968
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin E and clomiphene citrate for 6 months
Study: 3139285
Drug: 5-day rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day rIL-2 bolus (10^5 units/kg every 8 hours) followed by LAK cell infusion
Study: 3139285
Drug: 3-day rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day rIL-2 prime and 6-day continuous infusion rIL-2 (3 x 10^6 units/m2/day) with LAK cell infusion
Study: 3139285
Drug: LAK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAK cell infusion
Study: 23464951
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy with a licensed therapist
Study: 21439528
Drug: Very-low-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose heparin (2,000 IU)
Study: 21439528
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5,000 IU)
Study: 18192671
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.1 mg triptorelin) administered 6 days after ICSI
Study: 18192671
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 6 days after ICSI
Study: 16611715
Drug: eGFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <60 ml/min per 1.73 m²
Study: 16611715
Drug: eGFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <60 ml/min per 1.73 m² and >=2+ proteinuria
Study: 1740861
Drug: Educational memorandum
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational memorandum outlining vaccine indications
Study: 1740861
Drug: Vaccine offered
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine offered directly in clinics and conferences
Study: 6430053
Drug: Low-dose NTG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NTG patches (n = 7)
Study: 6430053
Drug: Maximally tolerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximally tolerated NTG patches (first type, n = 8, mean NTG dose delivered 25 mg)
Study: 6430053
Drug: Maximally tolerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximally tolerated NTG patches (second type, n = 5, mean NTG dose delivered 22 mg)